Oscotec Inc.
  • Company
    • About us
    • History
    • Leadership
    • Location
  • SCIENCE
    • PIPELINE
    • ACART
    • PUBLICATION
  • INVESTORS
    • Notice
    • Financial Info
    • IR Material
    • Press Releases
    • Public Disclosures
  • SUSTAINABILITY
    • Governance
      • Code of Ethics
      • Board
      • Committee
      • Audit
      • Articles of Inc.
    • ESG Portal
  • Contact
    • Contact us
    • Report a Concern
    • Privacy Policy
    • Careers
  • English
  • 한국어
  • English
  • 한국어

COMPANY

  • About us
  • History
  • Leadership
  • Location

SCIENCE

  • PIPELINE
  • ACART
  • Publication

INVESTORS

  • Notice
  • Financial Info
  • IR Material
  • Press Releases
  • Public Disclosures

Sustainability

  • Governance
    • Code of Ethics
    • Board
    • Committee
    • Audit
    • Articles of Inc.
  • ESG Portal

CONTACT

  • Contact us
  • Report a Concern
  • Privacy Policy
  • Careers
  • English
  • 한국어

Notice

Read our latest update

Oscotec Inc. Reports Q3 2026 Financial Results

Nov 13, 2026

Message to Our Shareholders Regarding the Licensing of Cevidoplenib

Jun 2, 2026

Oscotec Shareholder Letter_2026 Annual General Meeting

Mar 19, 2026

To the Shareholders of Oscotec

May 19, 2025

Oscotec The 27th Annual Meeting of Shareholders Reference Materials

Mar 13, 2025

Privacy Policy |  Company   |   SCIENCE   |    INVESTORS  |   SUSTAINABILITY  |  Contact
Address: 9F, Bldg. A, Korea Bio-Park, 700 Daewangpangyo-ro,
Bundang-gu, Seongnam-si, Gyeonggi-do 13488 Republic of Korea
CEO: Taeyoung Yoon, Sanghyun Lee
Business Registration No.: 312-81-32175











Contact
GENOSCO
Copyright © OSCOTEC Inc. 2026. All Rights Reserved.